Metropolis Healthcare Limited
NSE: METROPOLISMarket Closed • NSE
Day range
52 week range
Metropolis Healthcare Limited closed at INR530.35 (+1.41%) on volume 0.76x its 20-day average, trading 12.92% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +11.8% QoQ
2026-05-19
DIVIDEND Announced
Interim Dividend - Re 1 Per Share
2026-03-20
BONUS Announced
Bonus 3:1
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 17.8%
Low Debt Profile: Debt-to-Equity is comfortable at 0.15x
High Cash Flow Conversion: CFO/PAT averaged 1.83x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 54.6x
Bull case
Market Leadership: Established operational scale in Diagnostics & Research.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 19 May 2026 | Dividend | ₹1.00 / share | — | 19 May 2026 |
| 20 Mar 2026 | Bonus issue | 3:1 bonus ratio | — | 20 Mar 2026 |
| 11 Nov 2025 | Dividend | ₹4.00 / share | — | 11 Nov 2025 |
| 17 Nov 2023 | Dividend | ₹4.00 / share | — | 17 Nov 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 10 Aug 2023 |
| 23 Feb 2023 | Dividend | ₹8.00 / share | — | 23 Feb 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 08 Aug 2022 |
| 22 Feb 2022 | Dividend | ₹8.00 / share | — | 21 Feb 2022 |
| 19 Feb 2021 | Dividend | ₹8.00 / share | — | 17 Feb 2021 |
| 15 Feb 2020 | Dividend | ₹8.00 / share | — | 13 Feb 2020 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
IndiaHealthcare
Is Metropolis Healthcare Limited Shariah compliant?
Metropolis Healthcare Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (2.11%) complies with AAOIFI threshold (≤ 33%).
What is Metropolis Healthcare Limited's current valuation relative to peers?
Metropolis Healthcare Limited trades at a P/E of 54.6x compared to the sector median of 37x, and a Price-to-Book of 7.3x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.15x. Interest coverage is 10.9x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 6.4% while net profit growth averaged 8.3%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.